Cargando…

Clinical significance of soluble CD163 in polymyositis-related or dermatomyositis-related interstitial lung disease

BACKGROUND: Macrophage activation is involved in the pathogenesis of polymyositis (PM)/dermatomyositis (DM). CD163, a scavenger receptor expressed on the surface of activated macrophages, mediates anti-inflammatory functions. This study aimed to evaluate the clinical significance of soluble CD163 (s...

Descripción completa

Detalles Bibliográficos
Autores principales: Enomoto, Yasunori, Suzuki, Yuzo, Hozumi, Hironao, Mori, Kazutaka, Kono, Masato, Karayama, Masato, Furuhashi, Kazuki, Fujisawa, Tomoyuki, Enomoto, Noriyuki, Nakamura, Yutaro, Inui, Naoki, Suzuki, Daisuke, Ogawa, Noriyoshi, Nakashima, Ran, Mimori, Tsuneyo, Iwashita, Toshihide, Suda, Takafumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5248519/
https://www.ncbi.nlm.nih.gov/pubmed/28103926
http://dx.doi.org/10.1186/s13075-016-1214-8
_version_ 1782497284094689280
author Enomoto, Yasunori
Suzuki, Yuzo
Hozumi, Hironao
Mori, Kazutaka
Kono, Masato
Karayama, Masato
Furuhashi, Kazuki
Fujisawa, Tomoyuki
Enomoto, Noriyuki
Nakamura, Yutaro
Inui, Naoki
Suzuki, Daisuke
Ogawa, Noriyoshi
Nakashima, Ran
Mimori, Tsuneyo
Iwashita, Toshihide
Suda, Takafumi
author_facet Enomoto, Yasunori
Suzuki, Yuzo
Hozumi, Hironao
Mori, Kazutaka
Kono, Masato
Karayama, Masato
Furuhashi, Kazuki
Fujisawa, Tomoyuki
Enomoto, Noriyuki
Nakamura, Yutaro
Inui, Naoki
Suzuki, Daisuke
Ogawa, Noriyoshi
Nakashima, Ran
Mimori, Tsuneyo
Iwashita, Toshihide
Suda, Takafumi
author_sort Enomoto, Yasunori
collection PubMed
description BACKGROUND: Macrophage activation is involved in the pathogenesis of polymyositis (PM)/dermatomyositis (DM). CD163, a scavenger receptor expressed on the surface of activated macrophages, mediates anti-inflammatory functions. This study aimed to evaluate the clinical significance of soluble CD163 (sCD163) in PM/DM-related interstitial lung disease (ILD). METHODS: The main subjects were 48 patients with PM/DM-related ILD. As controls, 10 patients with PM/DM without ILD and 20 healthy volunteers were enrolled. In patients with PM/DM-related ILD, the baseline characteristics and clinical course were obtained through a review of patient medical records. Serum sCD163 levels at ILD diagnosis were quantified by enzyme-linked immunosorbent assay, which were compared with the other baseline clinical factors and evaluated for potential as a prognostic biomarker. In addition, immunohistochemistry analysis using anti-human CD163 antibody was performed on the lung sections of two patients with DM-related ILD (a survivor and non-survivor, respectively) and one patient with early-stage lung cancer as a normal control. RESULTS: The median value of serum sCD163 in patients with PM/DM-related ILD was 818 ng/mL, which was higher than that of PM/DM patients without ILD and healthy volunteers (716 ng/mL and 340 ng/mL, respectively). Significant but mild correlations with serum sCD163 levels were observed for serum C-reactive protein levels (r = 0.322) and % predicted forced vital capacity (r = −0.301) in patients with PM/DM-related ILD. A Cox proportional hazard model demonstrated that patients with PM/DM-related ILD and higher sCD163 levels had worse prognosis (age-adjusted and gender-adjusted hazard ratio per 100 ng/mL increase 1.27, 95% confidence interval 1.11–1.45, P <0.001). In immunohistochemistry analysis, compared with normal lung, alveolar infiltration of CD163-positive macrophages was evident in the lungs of patients with DM-related ILD. Especially, the finding was more severe in the non-survivor’s lung. CONCLUSIONS: Serum sCD163 might be a potential biomarker for predicting the severity and prognosis of PM/DM-related ILD. Our results suggest the importance of macrophage activation in the disease. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13075-016-1214-8) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5248519
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-52485192017-01-25 Clinical significance of soluble CD163 in polymyositis-related or dermatomyositis-related interstitial lung disease Enomoto, Yasunori Suzuki, Yuzo Hozumi, Hironao Mori, Kazutaka Kono, Masato Karayama, Masato Furuhashi, Kazuki Fujisawa, Tomoyuki Enomoto, Noriyuki Nakamura, Yutaro Inui, Naoki Suzuki, Daisuke Ogawa, Noriyoshi Nakashima, Ran Mimori, Tsuneyo Iwashita, Toshihide Suda, Takafumi Arthritis Res Ther Research Article BACKGROUND: Macrophage activation is involved in the pathogenesis of polymyositis (PM)/dermatomyositis (DM). CD163, a scavenger receptor expressed on the surface of activated macrophages, mediates anti-inflammatory functions. This study aimed to evaluate the clinical significance of soluble CD163 (sCD163) in PM/DM-related interstitial lung disease (ILD). METHODS: The main subjects were 48 patients with PM/DM-related ILD. As controls, 10 patients with PM/DM without ILD and 20 healthy volunteers were enrolled. In patients with PM/DM-related ILD, the baseline characteristics and clinical course were obtained through a review of patient medical records. Serum sCD163 levels at ILD diagnosis were quantified by enzyme-linked immunosorbent assay, which were compared with the other baseline clinical factors and evaluated for potential as a prognostic biomarker. In addition, immunohistochemistry analysis using anti-human CD163 antibody was performed on the lung sections of two patients with DM-related ILD (a survivor and non-survivor, respectively) and one patient with early-stage lung cancer as a normal control. RESULTS: The median value of serum sCD163 in patients with PM/DM-related ILD was 818 ng/mL, which was higher than that of PM/DM patients without ILD and healthy volunteers (716 ng/mL and 340 ng/mL, respectively). Significant but mild correlations with serum sCD163 levels were observed for serum C-reactive protein levels (r = 0.322) and % predicted forced vital capacity (r = −0.301) in patients with PM/DM-related ILD. A Cox proportional hazard model demonstrated that patients with PM/DM-related ILD and higher sCD163 levels had worse prognosis (age-adjusted and gender-adjusted hazard ratio per 100 ng/mL increase 1.27, 95% confidence interval 1.11–1.45, P <0.001). In immunohistochemistry analysis, compared with normal lung, alveolar infiltration of CD163-positive macrophages was evident in the lungs of patients with DM-related ILD. Especially, the finding was more severe in the non-survivor’s lung. CONCLUSIONS: Serum sCD163 might be a potential biomarker for predicting the severity and prognosis of PM/DM-related ILD. Our results suggest the importance of macrophage activation in the disease. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13075-016-1214-8) contains supplementary material, which is available to authorized users. BioMed Central 2017-01-19 2017 /pmc/articles/PMC5248519/ /pubmed/28103926 http://dx.doi.org/10.1186/s13075-016-1214-8 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Enomoto, Yasunori
Suzuki, Yuzo
Hozumi, Hironao
Mori, Kazutaka
Kono, Masato
Karayama, Masato
Furuhashi, Kazuki
Fujisawa, Tomoyuki
Enomoto, Noriyuki
Nakamura, Yutaro
Inui, Naoki
Suzuki, Daisuke
Ogawa, Noriyoshi
Nakashima, Ran
Mimori, Tsuneyo
Iwashita, Toshihide
Suda, Takafumi
Clinical significance of soluble CD163 in polymyositis-related or dermatomyositis-related interstitial lung disease
title Clinical significance of soluble CD163 in polymyositis-related or dermatomyositis-related interstitial lung disease
title_full Clinical significance of soluble CD163 in polymyositis-related or dermatomyositis-related interstitial lung disease
title_fullStr Clinical significance of soluble CD163 in polymyositis-related or dermatomyositis-related interstitial lung disease
title_full_unstemmed Clinical significance of soluble CD163 in polymyositis-related or dermatomyositis-related interstitial lung disease
title_short Clinical significance of soluble CD163 in polymyositis-related or dermatomyositis-related interstitial lung disease
title_sort clinical significance of soluble cd163 in polymyositis-related or dermatomyositis-related interstitial lung disease
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5248519/
https://www.ncbi.nlm.nih.gov/pubmed/28103926
http://dx.doi.org/10.1186/s13075-016-1214-8
work_keys_str_mv AT enomotoyasunori clinicalsignificanceofsolublecd163inpolymyositisrelatedordermatomyositisrelatedinterstitiallungdisease
AT suzukiyuzo clinicalsignificanceofsolublecd163inpolymyositisrelatedordermatomyositisrelatedinterstitiallungdisease
AT hozumihironao clinicalsignificanceofsolublecd163inpolymyositisrelatedordermatomyositisrelatedinterstitiallungdisease
AT morikazutaka clinicalsignificanceofsolublecd163inpolymyositisrelatedordermatomyositisrelatedinterstitiallungdisease
AT konomasato clinicalsignificanceofsolublecd163inpolymyositisrelatedordermatomyositisrelatedinterstitiallungdisease
AT karayamamasato clinicalsignificanceofsolublecd163inpolymyositisrelatedordermatomyositisrelatedinterstitiallungdisease
AT furuhashikazuki clinicalsignificanceofsolublecd163inpolymyositisrelatedordermatomyositisrelatedinterstitiallungdisease
AT fujisawatomoyuki clinicalsignificanceofsolublecd163inpolymyositisrelatedordermatomyositisrelatedinterstitiallungdisease
AT enomotonoriyuki clinicalsignificanceofsolublecd163inpolymyositisrelatedordermatomyositisrelatedinterstitiallungdisease
AT nakamurayutaro clinicalsignificanceofsolublecd163inpolymyositisrelatedordermatomyositisrelatedinterstitiallungdisease
AT inuinaoki clinicalsignificanceofsolublecd163inpolymyositisrelatedordermatomyositisrelatedinterstitiallungdisease
AT suzukidaisuke clinicalsignificanceofsolublecd163inpolymyositisrelatedordermatomyositisrelatedinterstitiallungdisease
AT ogawanoriyoshi clinicalsignificanceofsolublecd163inpolymyositisrelatedordermatomyositisrelatedinterstitiallungdisease
AT nakashimaran clinicalsignificanceofsolublecd163inpolymyositisrelatedordermatomyositisrelatedinterstitiallungdisease
AT mimoritsuneyo clinicalsignificanceofsolublecd163inpolymyositisrelatedordermatomyositisrelatedinterstitiallungdisease
AT iwashitatoshihide clinicalsignificanceofsolublecd163inpolymyositisrelatedordermatomyositisrelatedinterstitiallungdisease
AT sudatakafumi clinicalsignificanceofsolublecd163inpolymyositisrelatedordermatomyositisrelatedinterstitiallungdisease